XML 27 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
STOCK-BASED COMPENSATION PLANS
12 Months Ended
Sep. 30, 2016
STOCK-BASED COMPENSATION PLANS [Abstract]  
STOCK-BASED COMPENSATION PLANS
(5)   STOCK-BASED COMPENSATION PLANS

Under the Company’s 1996 Equity Incentive Plan (the “Plan”) there were 124,888 shares reserved and available for grant at September 30, 2016. There were 139,578 shares reserved and available for grant at September 30, 2015.  There were no options exercised in 2016 or in 2015.
 
The Plan, which is shareholder-approved, permits the grant of restricted stock, restricted stock units, stock options and stock appreciation rights (“SARs”).SARs may be awarded either separately, or in relation to options granted, and for the grant of bonus shares. Options granted are exercisable at a price not less than fair market value on the date of grant.
 
Stock options

The Company estimated the fair values of its stock options using the Black-Scholes-Merton option-pricing model, which was developed for use in estimating the fair values of stock options. Option valuation models, including the Black-Scholes-Merton option-pricing model, require the input of assumptions, including stock price volatility. Changes in the input assumptions can materially affect the fair value estimates and ultimately how much the Company recognizes as stock-based compensation expense. The fair values of the Company’s stock options were estimated at the grant dates. The weighted average input assumptions used and resulting fair values of stock options were as follows for 2016 (there were no stock options outstanding in 2015):
 
Executive and management options:

Expected life (in years)
  
4.0
 
Risk-free interest rate
  
1.55
%
Volatility
  
61.43
%
Dividend yield
  
0.00
%
Weighted-average fair value per share
 
$
4.81
 

Executive chairman options:

Expected life (in years)
  
4.0
 
Risk-free interest rate
  
0.99% - 1.14
%
Volatility
  
60.45% - 64.40
%
Dividend yield
  
0.00
%
Weighted-average fair value per share
 
$
3.69 - $4.03
 

Expected Life
The expected term represents the period of time that options are expected to be outstanding. As the Company does not have sufficient historical evidence for determining the expected term of the stock option awards granted, the expected life assumption has been determined using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.

Risk-free Interest Rate
The Company bases the risk-free interest rate assumption on zero-coupon U.S. treasury instruments appropriate for the expected term of the stock option grants.

Expected Volatility
The expected stock price volatility for the Company’s common stock is estimated based on the historic volatility of the Company’s common stock for a period equivalent to the expected term of the stock option grants.

Expected Dividend Yield
The Company bases the expected dividend yield assumption on the fact that there is no present intention to pay cash dividends. Therefore an expected dividend yield of zero has been used.

Performance based awards

Stock options:

In December 2015, the Compensation Committee awarded performance-based equity compensation to nine executives and managers, including the principal executive officer and principal financial officer, consisting of 38,460 shares in the form of stock options. The performance options have an exercise price of $9.94 per share, representing the average of the highest intraday bid and ask quotes for the Company’s common stock on the date of grant, December 16, 2015, and the preceding four trading days. The performance options will vest subject to the Company meeting an earnings per share target applicable to fiscal year 2018 set by the Compensation Committee so long as the employee is then employed by the Company.  The Company estimated the fair values of its stock options using the Black-Scholes-Merton option-pricing model. The estimated fair value of the stock options on the date of the grant was $185,000. The unvested compensation is being expensed over three years. The expense for this employee stock option grant will be approximately $14,000 on a quarterly basis.
 
A summary of performance based option activity under the share option plan as of September 30, 2016, and changes during the twelve months then ended is presented below:

  
Shares
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
Term (Years)
  
Aggregate
Intrinsic
Value
 
Outstanding as of September 30, 2015
  
-
  
 
-
   
-
  
 
-
 
Granted – Executives and management
  
38,460
  
 
9.94
   
4.21
  
 
-
 
Exercised
  
-
   
-
   
-
   
-
 
Forfeited or Expired
  
-
   
-
   
-
   
-
 
Outstanding at September 30, 2016
  
38,460
  
 
9.94
   
4.21
  
$
-
 
Exercisable
  
-
   
-
   
-
   
-
 
Vested and expected to vest
  
35,088
  
 
9.94
   
4.21
  
$
-
 

Restricted stock:

In December 2015, the Company granted 11,540 shares of restricted stock to four employees which will vest subject to the Company meeting the same earnings per share target applicable to fiscal year 2018 as for the stock options disclosed above, so long as the employee is then employed by the Company. The estimated fair value of the stock on the date of the grant was $116,000 based on the fair market value of stock on the date of issue. The unvested compensation is being expensed over three years. The expense for this employee stock option grant was $27,000 for the twelve months ended September 30, 2016 and will be approximately $9,000 on a quarterly basis.

Management has assessed the performance criteria relating to these grants and concluded they are likely to be met. Accordingly the relevant portion of the expense has been recorded for the twelve months ended September 30, 2016.

Time-based awards

Stock options:

In August 2016, the Board of Directors awarded the Executive Chairman equity compensation consisting of stock options to purchase 56,700 shares. The options were granted in two tranches. The first tranche, consisting of 36,496 options with an exercise price of $10.93 per share, would vest in twelve substantially equal monthly installments beginning September 2016, and the second tranche, consisting of 20,204 options with an exercise price of $12.35 per share, would vest in twelve substantially equal monthly installments beginning September 2017, in each case so long as the director is in the position of Executive Chairman.  The Company estimated the fair values of its stock options using the Black-Scholes-Merton option-pricing model. The estimated fair value of the stock options on the date of the grant was $211,000.  The Executive Chairman position was terminated on December 6, 2016, as a result of which 12,165 vested options are exercisable for three months, and all unvested options expired. The expense for these restricted stock grants in the twelve months ended September 30, 2016 was $22,000.
 
A summary of time based option activity under the share option plan as of September 30, 2016, and changes during the twelve months then ended is presented below:
 
  
Shares
  
Weighted
Average
Exercise
Price
  
Weighted
Average
Remaining
Contractual
Term (Years)
  
Aggregate
Intrinsic
Value
 
Outstanding as of September 30, 2015
  
-
  
 
-
   
-
  
 
-
 
Granted – Executive Chairman
  
56,700
  
 
11.43
   
4.08
  
 
-
 
Exercised
  
-
   
-
   
-
   
-
 
Forfeited or Expired
  
(44,535
)
 
 
10.93
   
-
   
-
 
Outstanding at September 30, 2016
  
12,165
  
 
10.93
   
4.08
  
$
-
 
Exercisable
  
-
   
-
   
-
   
-
 
Vested and expected to vest
  
12,165
  
 
10.93
   
4.08
  
$
-
 

Restricted stock:

In February 2016, the Company granted 29,700 shares of restricted stock to nine non-employee directors, which will vest on the day before the 2017 annual general meeting providing that the grantee remains a director of the Company, or as otherwise determined by the Compensation Committee.  The aggregate fair value of the stock measured on the date of the grant was $292,000 based on the closing sale price of the stock on the date of grant.  Subsequent to this, 3,300 of these granted shares of restricted stock were cancelled and returned to the Plan following the resignation of a director. Compensation expense is being expensed on a straight line basis over the twelve month period during which the forfeiture conditions lapse.  The charge to income for these restricted stock grants in the twelve months to September 30, 2016 was $151,000 and the subsequent charge will be approximately $65,000 on a quarterly basis.

For the purposes of calculating average issued shares for basic earnings per share these shares are only considered to be outstanding when the forfeiture conditions lapse and the shares vest.

A summary of restricted stock and stock option activity, including both performance based awards and time-based awards, for the twelve months ended September 30, 2016 and 2015 is as follows:

  
Number of shares of
Restricted Stock
  
Weighted Average
Grant-Date Fair Value
 
Non-vested balance as of September 30, 2014
  
168,600
  
$
5.27
 
Granted
  
92,600
  
$
7.49
 
Vested
  
(64,600
)
 
$
6.32
 
Non-vested balance as of September 30, 2015
  
196,600
  
$
5.97
 
Granted
  
41,240
  
$
9.89
 
Cancelled
  
(3,300
)
 
$
9.82
 
Vested
  
(95,600
)
 
$
6.77
 
Non-vested balance as of September 30, 2016
  
138,940
  
$
6.50
 

  
Number of shares of
Stock Options
  
Weighted Average
Grant-Date Fair Value
 
Non-vested balance as of September 30, 2015
  
-
  
$
-
 
Granted
  
95,160
  
$
4.67
 
Cancelled
  
(44,535
)
 
$
-
 
Non-vested balance as of September 30, 2016
  
50,625
  
$
4.67
 

Stock-based compensation expense was $754,000 and $554,000 for the years ended September 30, 2016 and 2015, respectively.  At September 30, 2016, there was $490,830 of unrecognized compensation expense related to restricted stock and stock options granted under the Plan. The Company expects to recognize that cost over a weighted average period of 1.7 years.